U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H18ClN.ClH
Molecular Weight 248.192
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEFENOREX HYDROCHLORIDE

SMILES

Cl.CC(CC1=CC=CC=C1)NCCCCl

InChI

InChIKey=IDHNGYVCZUQHFV-UHFFFAOYSA-N
InChI=1S/C12H18ClN.ClH/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12;/h2-4,6-7,11,14H,5,8-10H2,1H3;1H

HIDE SMILES / InChI
Molecular Formula C12H18ClN
Molecular Weight 211.731
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including, http://ec.europa.eu/health/documents/community-register/2000/200003093430/anx_3430_en.pdf

Mefenorex or (+/-)N-(3-chloropropyl)-1-methyl-2-phenylethylamine is an N-alkylated analogue of amphetamine. The therapeutic efficacy of mefenorex as an adjunctive support in the treatment of obesity for limited periods of time, as well as its ability to be well tolerated, has been amply demonstrated. Mefenorex is considered to be racemic mixture, no available data regarding enantiospecific pharmacological activity of the compound.

CNS Activity

Originator

Hoffman-La Roche
134
Curator's Comment: # Hoffmann-La Roche

Approval Year

Unknown
139594
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Withdrawn
Pondinil

Approved Use

Adjunctive therapy to diet, in patients with obesity and a body mass index (BMI) of 30 kg/m2 or higher who have not responded to an appropriate weight-reducing regimen alone

Launch Date

1970
PubMed

PubMed

TitleDatePubMed
Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.
2002 Apr
Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results.
2002 May
Impaired cognition and attention in adults: pharmacological management strategies.
2007 Feb
Patents

Patents

DE1210873
4
JP2001524960A
10

Sample Use Guides

In Vivo Use Guide
40 mg/day
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:28:56 GMT 2023
Edited
by admin
on Fri Dec 15 15:28:56 GMT 2023
Record UNII
6X1N18AU15
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEFENOREX HYDROCHLORIDE
MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
RO-4-5282
Code English
Mefenorex hydrochloride [WHO-DD]
Common Name English
N-(3-Chloropropyl)-α-methylphenethylamine hydrochloride
Systematic Name English
MEFENOREX HYDROCHLORIDE [MART.]
Common Name English
MEFENOREX HYDROCHLORIDE [MI]
Common Name English
(±)-MEFENOREX HYDROCHLORIDE
Common Name English
MEFENOREX HYDROCHLORIDE [USAN]
Common Name English
RO 4-5282
Code English
NSC-133749
Code English
MEFENOREX HYDROCHLORIDE, (±)-
Common Name English
MEFENOREX HCL
Common Name English
MEFENOREX HYDROCHLDRIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29728
Created by admin on Fri Dec 15 15:28:57 GMT 2023 , Edited by admin on Fri Dec 15 15:28:57 GMT 2023
Code System Code Type Description
PUBCHEM
21776
Created by admin on Fri Dec 15 15:28:57 GMT 2023 , Edited by admin on Fri Dec 15 15:28:57 GMT 2023
PRIMARY
SMS_ID
100000086166
Created by admin on Fri Dec 15 15:28:57 GMT 2023 , Edited by admin on Fri Dec 15 15:28:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL2110962
Created by admin on Fri Dec 15 15:28:56 GMT 2023 , Edited by admin on Fri Dec 15 15:28:56 GMT 2023
PRIMARY
ECHA (EC/EINECS)
226-985-9
Created by admin on Fri Dec 15 15:28:57 GMT 2023 , Edited by admin on Fri Dec 15 15:28:57 GMT 2023
PRIMARY
MERCK INDEX
m7140
Created by admin on Fri Dec 15 15:28:57 GMT 2023 , Edited by admin on Fri Dec 15 15:28:57 GMT 2023
PRIMARY Merck Index
MESH
C000450
Created by admin on Fri Dec 15 15:28:57 GMT 2023 , Edited by admin on Fri Dec 15 15:28:57 GMT 2023
PRIMARY
EVMPD
SUB03115MIG
Created by admin on Fri Dec 15 15:28:56 GMT 2023 , Edited by admin on Fri Dec 15 15:28:56 GMT 2023
PRIMARY
NSC
133749
Created by admin on Fri Dec 15 15:28:57 GMT 2023 , Edited by admin on Fri Dec 15 15:28:57 GMT 2023
PRIMARY
FDA UNII
6X1N18AU15
Created by admin on Fri Dec 15 15:28:57 GMT 2023 , Edited by admin on Fri Dec 15 15:28:57 GMT 2023
PRIMARY
NCI_THESAURUS
C77848
Created by admin on Fri Dec 15 15:28:57 GMT 2023 , Edited by admin on Fri Dec 15 15:28:57 GMT 2023
PRIMARY
CAS
5586-87-8
Created by admin on Fri Dec 15 15:28:56 GMT 2023 , Edited by admin on Fri Dec 15 15:28:56 GMT 2023
PRIMARY
RXCUI
236179
Created by admin on Fri Dec 15 15:28:57 GMT 2023 , Edited by admin on Fri Dec 15 15:28:57 GMT 2023
PRIMARY RxNorm
Related Record Type Details
Structure of MEFENOREX HYDROCHLORIDE, (R)-
ENANTIOMER -> RACEMATE
Structure of MEFENOREX HYDROCHLORIDE, (S)-
ENANTIOMER -> RACEMATE
Structure of MEFENOREX
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of MEFENOREX
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966